A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, vehicle-control study of 0.05% and 0.2% E6005 ointment.
Pediatric subjects with atopic dermatitis (AD) will be grouped into two; an elder group
(childhood - adolescent: 7 to 15 years of age) and a younger group (children: 2 to 6 years of
age) according to the sequential cohorts by confirming the safety.